Holen Sie sich die Stockscreener-App
19.85
7.30%
1.35
Vorhandelsmarkt:
19.78
-0.07
-0.35%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Ultragenyx Pharmaceutical Stock Hits Day Low of $18.29 Amid Price Pressure - Markets Mojo
Ultragenyx Pharmaceutical Hits Day Low at $19.86 Amid Price Pressure - Markets Mojo
Ultragenyx Pharmaceutical Hits 52-Week Low at $18.29 Amidst Declining Performance - Markets Mojo
Lost Money on Ultragenyx Pharmaceutical Inc.(RARE)? Join Class A - GuruFocus
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors - GlobeNewswire
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - GlobeNewswire Inc.
RARE Investor Alert: Ultragenyx Pharmaceutical Inc. Stockholders with Large Losses Should Contact Ro - pharmiweb.com
Bragar Eagel & Squire, P.C. Reminds Ultragenyx (NASDAQ: - GlobeNewswire
RARE Investor Alert: Ultragenyx Pharmaceutical Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit - The AI Journal
Ultragenyx Nears Key Inflection Point With Completed Phase 3 Gene Therapy Study in GSDIa - TipRanks
Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
Lost Money on Ultragenyx Pharmaceutical Inc.(RARE)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - Morningstar
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Q4 2025 earnings call transcript - MSN
Momentum Shift: Will Ultragenyx Pharmaceutical Inc outperform tech stocksGold Moves & Free Community Supported Trade Ideas - baoquankhu1.vn
Why Ultragenyx (RARE) Is Down 14.4% After Positive Phase 3 DTX301 Gene Therapy Results - simplywall.st
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 - GlobeNewswire
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - GlobeNewswire Inc.
Goldman Sachs Downgrades Ultragenyx (RARE), Slashes Price Target by 59% | RARE Stock News - GuruFocus
Goldman Sachs downgrades Ultragenyx Pharma stock rating to neutral By Investing.com - Investing.com India
Goldman Sachs Downgrades Ultragenyx (RARE) Following Trial Setba - GuruFocus
Ultragenyx Pharmaceutical (NASDAQ:RARE) Sets New 1-Year Low After Analyst Downgrade - MarketBeat
Ultragenyx downgraded to neutral at Goldman Sachs on setrusumab data - Seeking Alpha
Ultragenyx stock hits 52-week low at 18.36 USD - Investing.com
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Rating Lowered by The Goldman Sachs Group - MarketBeat
Portnoy Law Firm Announces Class Action on Behalf of Ultragenyx Pharmaceutical, Inc. Investors - GlobeNewswire
Goldman Sachs Downgrades Ultragenyx Pharmaceutical to Neutral From Buy, Adjusts PT to $25 From $61 - marketscreener.com
Goldman Sachs downgrades Ultragenyx Pharma stock rating to neutral - Investing.com UK
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investor Alert: Deadline in Lawsuit on April 6, 2026 - openPR.com
INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) - GlobeNewswire
RARE Investors Have Opportunity to Lead Ultragenyx - GlobeNewswire
RARE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - Sahm
WOODSTOCK CORP's Ultragenyx Pharmaceutical Inc(RARE) Holding History - GuruFocus
Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx - GlobeNewswire
2026-03-22 | RARE SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ultragenyx Pharmaceutical Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:RARE | Press Release - Stockhouse
Is It Time To Reconsider Ultragenyx Pharmaceutical (RARE) After A 47% One-Year Share Price Fall - Sahm
RARE DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ultragenyx Pharmaceutical ... - Caledonian Record
RARE DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
How Ultragenyx Pharmaceutical Inc. (RARE) Affects Rotational Strategy Timing - Stock Traders Daily
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Two new Ultragenyx hires get 10,839 stock units under Nasdaq rule - Stock Titan
A Look At Ultragenyx Pharmaceutical’s Valuation After Recent Share Price Weakness - Yahoo Finance
Mucopolysaccharidosis Treatment Market to Reach US$6.76 - openPR.com
INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action LawsuitRGRD Law - Lelezard
RARE Stock Price, Quote & Chart | ULTRAGENYX PHARMACEUTICAL IN (NASDAQ:RARE) - ChartMill
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit - ChartMill
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming DeadlinesRARE - PR Newswire
RARE DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. ... - Caledonian Record
RARE DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, - GlobeNewswire
RARE CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) ... - Bluefield Daily Telegraph
LEVI & KORSINSKY, LLP: FRAUD-ON-THE-MARKET DOCTRINE UNDERPINS ULTRAGENYX PHARMACEUTICAL SECURITIES CLASS ACTION (2026-03-18) - Seeking Alpha
LEVI & KORSINSKY, LLP: FRAUD-ON-THE-MARKET DOCTRINE UNDERPINS ULTRAGENYX PHARMACEUTICAL SECURITIES CLASS ACTION - Sahm
INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. Investors - GlobeNewswire
DTX301 Gene Therapy Lowers Ammonia Levels in Ornithine Transcarbamylase Deficiency at 36 Weeks - Neurology Live
RARE Shareholder Alert: Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm - PR Newswire
Aquatic Capital Management LLC Increases Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Phase 3 DTX301 Gene Therapy Data Could Be A Game Changer For Ultragenyx Pharmaceutical (RARE) - Sahm
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):